Chr t(15;17)

P=N/A, N=400, Active, not recruiting, Groupe Francophone des Myelodysplasies | Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Jul 2026 | Trial primary completion date: Oct 2020 --> Jul 2026

The rare genetic co-occurrence of t(15;17)/PML::RARA and t(9;22)/BCR::ABL1 translocations may be identified in a single patient with acute promyelocytic leukaemia (APL).Successful induction using all-trans retinoic acid (ATRA) together with imatinib achieved effective control of both leukemic clones.The patient demonstrated rapid haematologic remission and favourable clinical recovery, suggesting a positive outcome with this therapeutic approach.

Personalized treatment strategies may improve outcomes. However, multicenter studies are needed to validate these findings and identify novel therapeutic targets.

P1, N=66, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

PSP-0119 is metabolically stable, retaining 71% of parent compound at 60 minutes in human liver microsomes. In summary, IRAK4 degradation via PSP-0119 as a promising therapeutic strategy for treatment of FLT3-mutant AML.

To our knowledge, this isoform differs from all previously described PML::RARα fusion transcripts. This case emphasizes the importance of molecular characterization in APL diagnosis and minimal residual disease (MRD) monitoring, though further studies are required to establish its clinical correlation.

P2, N=178, Active, not recruiting, National Cancer Institute (NCI)

This study reinforces the effectiveness of ATRA-ATO-based regimens in managing paediatric APL. However, induction-related complications such as febrile neutropenia, transaminitis, and QTc prolongation highlight the need for vigilant monitoring and robust supportive care. Timely diagnosis and early initiation of therapy remain key to improving outcomes.

t(15;17)(q21;p11.2) is a novel cytogenetic abnormality in AML, along with the B2M-RARA fusion, and warrants thorough evaluation to rule out APL.

The patient achieved stable disease post-ruxolitinib treatment. This case highlights a unique molecular-pathological profile, suggesting NF1::SCAMP5 may define a provisional MPN subtype with distinct genetic features, warranting further study to elucidate its clinical significance.

It is also the first variant APL with der(11)(p15)t(11;17)(p15;q21) and i(17)(q10) chromosome abnormalities. Therefore, we compared and summarized these two cases.

P1, N=153, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Jul 2024 --> Jul 2026